Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381909 · ClinicalTrials.gov registry record · Phase 1
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
NCT05381909: Clinical Trial Phase 1 study, sponsored by BeiGene.
NCT05381909 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 157 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05381909, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
Study Summary
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
Primary Outcome
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs ), and experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG BGB-24714
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2022-07-06 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 1 |
Why NCT05381909 stopped before completion
NCT05381909 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT05381909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05381909 about?
NCT05381909 is a clinical study titled "A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors". This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered...
What is the current status of trial NCT05381909?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2022-07-06. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT05381909?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), BGB-24714 (DRUG).
Who is sponsoring clinical trial NCT05381909?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05381909's enrollment target sits among peer trials
157 351st of 2000 higher than 1,650 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI